487 related articles for article (PubMed ID: 7982257)
1. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
González MA; Kisicki J; Straughn AB
Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
[TBL] [Abstract][Full Text] [Related]
2. Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur).
Oosterhuis B; Brannan MD; Groen H; Peeters PA; Hempenius J; Radwanski E; Nomeir AA; Affrime MB; Jonkman JH
Ann Allergy Asthma Immunol; 1995 Aug; 75(2):157-61. PubMed ID: 7648380
[TBL] [Abstract][Full Text] [Related]
3. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
González MA; Straughan AB
Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
[TBL] [Abstract][Full Text] [Related]
4. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men.
Dockhorn RJ; Cefali EA; Straughn AB
Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214
[TBL] [Abstract][Full Text] [Related]
5. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
[TBL] [Abstract][Full Text] [Related]
6. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily.
Götz J; Sauter R; Steinijans VW; Jonkman JH
Int J Clin Pharmacol Ther; 1994 Apr; 32(4):168-73. PubMed ID: 8032575
[TBL] [Abstract][Full Text] [Related]
8. Variations in absorption of theophylline from two sustained-release products.
Ferrari M; Olivieri M; Barozzi E; Ramponi C
Clin Ther; 1986; 8(6):646-54. PubMed ID: 3791362
[TBL] [Abstract][Full Text] [Related]
9. Once-a-day dosing with theophylline: a comparison of four sustained-release products.
Minotti DA; Altman LC; Ayars GH; Popick FR; Benn VJ
Ann Allergy; 1992 Jun; 68(6):500-6. PubMed ID: 1610026
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677
[TBL] [Abstract][Full Text] [Related]
11. Theophylline absorption from two sustained-release products. Implications for therapeutic drug monitoring.
Rogers RJ; Wiener MB; Hill MR; Szefler SJ
Am Rev Respir Dis; 1987 Nov; 136(5):1168-73. PubMed ID: 3674579
[TBL] [Abstract][Full Text] [Related]
12. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
Hurwitz A; Karim A; Burns TS
J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
[TBL] [Abstract][Full Text] [Related]
13. Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients.
Ferrari M; Olivieri M; Lampronti G; Bonazza L; Biasin C; Nacci P; Talamini G; Lo Cascio V
Thorax; 1997 Nov; 52(11):969-74. PubMed ID: 9487345
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release theophylline. Pharmacokinetic and therapeutic comparison of two preparations.
Menendez R; Kelly HW; Howick J; McWilliams BC
Am J Dis Child; 1983 May; 137(5):469-73. PubMed ID: 6846276
[TBL] [Abstract][Full Text] [Related]
15. Absorption of sustained-release theophylline tablets.
Fagerström PO; Heintz L
Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
[TBL] [Abstract][Full Text] [Related]
16. Absorption of theophylline from conventional and sustained-release tablets.
Mellstrand T; Svedmyr N; Fagerström PO
Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of a slow-release theophylline capsule given twice daily to preschool children with chronic asthma: comparison with liquid theophylline.
Sallent J; Hill M; Stecenko A; McKenzie M; Hendeles L
Pediatrics; 1988 Jan; 81(1):116-20. PubMed ID: 3336577
[TBL] [Abstract][Full Text] [Related]
18. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
[TBL] [Abstract][Full Text] [Related]
19. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
Weinberger MM
Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of a generic slow-release theophylline tablet in children.
Kanthawatana S; Ahrens RC; McCubbin M; Bronsky E; Blake K; Hendeles L
J Pediatr; 1994 Dec; 125(6 Pt 1):987-91. PubMed ID: 7996375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
